Novel CDKN2A mutations detected in western Swedish families with hereditary malignant melanoma

J Invest Dermatol. 2007 Jun;127(6):1465-7. doi: 10.1038/sj.jid.5700718. Epub 2007 Jan 25.

Abstract

We have examined alterations in the cyclin-dependent kinase inhibitor 2A (CDKN2A), a major melanoma predisposing gene, in a western-Swedish hereditary melanoma population comprising 107 patients from 68 families. Using sequence analysis and multiplex ligation-dependent probe amplification, we found a novel mutation (Asp108 Tyr), segregating with the disease in three families. This mutation has previously been detected as a somatic mutation in other cancers. We found a previously described Swedish founder mutation (ins113Arg) in one family and a large duplication encompassing the CDKN2A gene locus in another family. Moreover, a debated polymorphism (Ala148Thr) was found in nine families, in which the polymorphism did not segregate with the disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cyclin-Dependent Kinase Inhibitor p16 / genetics*
  • Family Health
  • Female
  • Founder Effect
  • Genetic Variation
  • Humans
  • Male
  • Melanoma / genetics*
  • Pedigree
  • Phenotype
  • Point Mutation*
  • Skin Neoplasms / genetics*
  • Sweden

Substances

  • Cyclin-Dependent Kinase Inhibitor p16